logo

For the Inventor, By the Inventor

Bethesda, MD, United States of America

Henry C Krutzsch

This inventor holds 18 USPTO granted patents and 1 published patent application, plus 1 CIPO patent, primarily in Peptide Therapeutics. Top assignees: The United States of America as Represented by the Department of Health, The United States of America, as Represented by the Secretary, Department of Health and Human Services, The United States of America as Represented by the Secretary of. Active years: 1993-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Henry C Krutzsch. Retrieved from https://idiyas.com/inventor/henry-c-krutzsch

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 77.8

 

Average Co-Inventor Count = 3.1

ph-index = 10

Forward Citations = 223(Granted Patents)


Company Filing History:

goldMedal8 out of 1,217 
 
The United States of America as Represented by the Department of Health
 patents
silverMedal5 out of 3,713 
 
The United States of America, as Represented by the Secretary, Department of Health and Human Services
 patents
bronzeMedal2 out of 2,202 
 
The United States of America as Represented by the Secretary of
 patents
4. 1 out of 644 
 
The UAB Research Foundation (The University of Alabama at Birmingham)
 patents
5. 2 out of 834,708 
Other
 patents

Years Active: 1993-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
Peptides
Cancer Treatment
Cell Adhesion
Metalloproteinases
Thrombospondin
TGF-Beta Activation
Kidney Disease
AAMP-1
Fibronectin Inhibitors
Semenogelin
Diagnostic Methods
Therapeutic Compositions
18 patents (USPTO):Explore Patents
1. 8114406 - Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins (2012-02-14),
2. 7745144 - Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins (2010-06-29),
3. 7618789 - Use of semenogelin in the diagnosis, prognosis and treatment of cancer (2009-11-17),
4. 7129052 - Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins (2006-10-31),
5. 6458767 - Use of peptides inhibitory for thrombospondin dependent TGF-&bgr; activation in the treatment of kidney disease (2002-10-01),
6. 6384189 - Compositions for stimulating TGF-&bgr; activity (2002-05-07),
7. 6274134 - Human cell adhesion protein AAMP-1 and uses thereof (2001-08-14),
8. 6051549 - Heparin and sulfatide binding peptides from the type-I repeats of human (2000-04-18),
9. 5849701 - Peptide inhibitors of fibronectin and related collagen-binding proteins (1998-12-15),
10. 5770563 - Heparin- and sulfatide binding peptides from the type I repeats of human (1998-06-23),
11. 5698671 - Metalloproteinase peptides (1997-12-16),
12. 5595885 - Matrix metalloproteinase inhibitor peptides (1997-01-21),
13. 5491130 - Peptide inhibitors of fibronectin and related collagen-binding proteins (1996-02-13),
14. 5449753 - Autotaxin: motility stimulating protein useful in cancer diagnosis (1995-09-12),
15. 5372809 - Antigenic matrix metalloproteinase peptides (1994-12-13),

Title: Innovations of Henry C Krutzsch

Introduction

Henry C Krutzsch is a notable inventor based in Bethesda, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of peptides and their applications in cell behavior modulation. With a total of 18 patents, his work has had a profound impact on medical research and therapeutic applications.

Latest Patents

One of his latest patents focuses on peptides and their utility in modulating the behavior of cells expressing α3β1 integrins. This invention describes a peptide comprising a specific sequence that can inhibit cell adhesion, motility, and proliferation, while promoting other cellular processes. The patent also covers the development of peptide-substrate combinations suitable for cell growth, as well as applications in vascular grafts and artificial blood vessels. Additionally, it includes pharmaceutical compositions and methods for inhibiting angiogenesis using these peptides.

Career Highlights

Throughout his career, Henry C Krutzsch has worked with the United States of America as represented by the Department of Health and the National Institutes of Health, a component of the US Department of Health & Human Services. His work has been instrumental in advancing the understanding of peptide interactions and their potential therapeutic uses.

Collaborations

Henry has collaborated with notable colleagues such as David D Roberts and Lance A Liotta, contributing to a rich exchange of ideas and innovations in the field of biotechnology.

Conclusion

Henry C Krutzsch's innovative work in peptide research has led to numerous patents and significant advancements in medical science. His contributions continue to influence the development of new therapeutic strategies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…